摘要
过去十年来,药物发现方面的公私伙伴关系一直在增加,主要是由于生产力下降,成本高昂,时间和需要的资源以及监管机构的要求等因素。在这种情况下,传统的计算机辅助药物发现技术已经发挥了重要作用,能够在早期阶段鉴定新的分子实体。然而,最近在化学信息学和系统药理学方面的进展,以及越来越多的高质量,可公开获得的药物化学数据,导致出现了新的计算机方法。这些新颖的方法能够将大量的多种化学和生物数据整合到一个建模方程中。本评论分析了两种主要类型的计算机方法中的前沿。在第一部分中,我们讨论了定量结构 - 生物效应关系(mtk-QSBER)的多任务模型的更新,其应用在过去几年中显着增加。在第二部分中,我们提供了有关将扰动理论与定量结构 - 性质关系建模工具(pt-QSPR)相结合的新方法的详细信息。最后,最重要的是,我们表明,联合使用mtk-QSBER和pt-QSPR建模工具可以通过多个阶段来引导药物发现:从体外测定到临床前研究和临床试验。
关键词: Box-Jenkins移动平均线,CHEMBL,知识发生器,mtk-QSBER模型,扰动理论,pt-QSPR模型。
Current Medicinal Chemistry
Title:Advanced In Silico Approaches for Drug Discovery: Mining Information from Multiple Biological and Chemical Data Through mtk- QSBER and pt-QSPR Strategies
Volume: 24 Issue: 16
关键词: Box-Jenkins移动平均线,CHEMBL,知识发生器,mtk-QSBER模型,扰动理论,pt-QSPR模型。
摘要: The last decade has been seeing an increase of public-private partnerships in drug discovery, mostly driven by factors such as the decline in productivity, the high costs, time, and resources needed, along with the requirements of regulatory agencies. In this context, traditional computer-aided drug discovery techniques have been playing an important role, enabling the identification of new molecular entities at early stages. However, recent advances in chemoinformatics and systems pharmacology, alongside with a growing body of high quality, publicly accessible medicinal chemistry data, have led to the emergence of novel in silico approaches. These novel approaches are able to integrate a vast amount of multiple chemical and biological data into a single modeling equation. The present review analyzes two main kinds of such cutting-edge in silico approaches. In the first subsection, we discuss the updates on multitasking models for quantitative structure-biological effect relationships (mtk- QSBER), whose applications have been significantly increasing in the past years. In the second subsection, we provide detailed information regarding a novel approach that combines perturbation theory with quantitative structure-property relationships modeling tools (pt- QSPR). Finally, and most importantly, we show that the joint use of mtk-QSBER and pt- QSPR modeling tools are apt to guide drug discovery through its multiple stages: from in vitro assays to preclinical studies and clinical trials.
Export Options
About this article
Cite this article as:
Advanced In Silico Approaches for Drug Discovery: Mining Information from Multiple Biological and Chemical Data Through mtk- QSBER and pt-QSPR Strategies, Current Medicinal Chemistry 2017; 24 (16) . https://dx.doi.org/10.2174/0929867324666170124152746
DOI https://dx.doi.org/10.2174/0929867324666170124152746 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Genetic Determinants of Severe Respiratory Syncytial Virus Infection and Post-Bronchiolitis Wheeze: A Systematic Review
Current Respiratory Medicine Reviews Inflammaging and Proteases in Abdominal Aortic Aneurysm
Current Vascular Pharmacology Implantable Medical Devices and Tissue Engineering: An Overview of Manufacturing Processes and the Use of Polymeric Matrices for Manufacturing and Coating their Surfaces
Current Medicinal Chemistry Pragmatic Analysis of Dyslipidemia Involvement in Coronary Artery Disease: A Narrative Review
Current Cardiology Reviews Cytochrome P450s: Mechanisms and Biological Implications in Drug Metabolism and its Interaction with Oxidative Stress
Current Drug Metabolism Genetically Modified Endothelial Progenitor Cells in the Therapy of Cardiovascular Disease and Pulmonary Hypertension
Current Vascular Pharmacology Stem Cell Therapies for the Lysosomal Storage Diseases – the Quintessential Neurodegenerative Diseases
Current Stem Cell Research & Therapy Repetitive Transcranial Magnetic Stimulation to Treat Substance Use Disorders and Compulsive Behavior
CNS & Neurological Disorders - Drug Targets Application of Hematopoietic Cells to Therapeutic Angiogenesis
Current Pharmaceutical Design Predictors of Ominous Outcome in Infants who Undergo Cardiac Surgery and Cardiopulmonary By-Pass: S100B Protein
CNS & Neurological Disorders - Drug Targets On the Interaction Between Human IQGAP1 and Actin
Protein & Peptide Letters ATP Binding Cassette Transporter A1 (ABCA1) Associated Proteins:Potential Drug Targets in the Metabolic Syndrome and Atherosclerotic Disease?
Current Pharmaceutical Biotechnology Diagnosis of Vulnerable Plaque and Vulnerable Patient by Coronary Angioscopy and Multi-detector Row Computed Tomography (MDCT) — From Invasive to Non-invasive Plaque Imaging
Vascular Disease Prevention (Discontinued) Interventions to Reduce Cardiovascular Risk in Children with Type 1 Diabetes
Current Diabetes Reviews Gene-Gene and Gene-Clinical Factors Interaction in Acute Myocardial Infarction: A New Detailed Risk Chart
Current Pharmaceutical Design Patients with Prehypertension - Do we have Enough Evidence to Treat them?
Current Vascular Pharmacology Polypharmacological Properties and Therapeutic Potential of β-Caryophyllene: A Dietary Phytocannabinoid of Pharmaceutical Promise
Current Pharmaceutical Design Editorial [Hot Topic: New Drug Targets for the Treatment of Asthma (Guest Editor: D. Knight)]
Current Drug Targets Antiplatelet Therapies: Aspirin at the Heart of New Directions
Cardiovascular & Hematological Disorders-Drug Targets Treatment of Carotid Stenosis
Current Vascular Pharmacology